Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Delirium and dementia are two frequent causes of cognitive impairment among older adults
and have a distinct, complex and interconnected relationship. Delirium is an acute …

The quantification of phosphorylated tau in biofluids, either cerebrospinal fluid (CSF) or
plasma, has shown great promise in detecting Alzheimer's disease (AD) pathophysiology …

Alzheimer's disease is a progressive, irreversible neurodegenerative disease impacting
cognition, function, and behavior. Alzheimer's disease progresses along a continuum from …

Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …

Alzheimer's disease (AD) is the most common type of dementia. Its diagnosis and
progression detection have been intensively studied. Nevertheless, research studies often …

Summary Loss-of-function (LOF) variants of TREM2, an immune receptor expressed in
microglia, increase Alzheimer's disease risk. TREM2 senses lipids and mediates myelin …